ARISE
Affording Recovery In Stroke
| Coordinatore | CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://www.arise-europe.net/index-preview.php |
| Totale costo | 16˙246˙309 € |
| EC contributo | 11˙246˙776 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-IP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-03-01 - 2013-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | coordinator | 0.00 |
| 2 |
Nome Ente NON disponibile
Organization address
address: YLIOPISTONRANTA 1 E contact info |
FI (Kuopio) | participant | 0.00 |
| 3 |
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Organization address
address: CALLE ROSSELLO 149 PUERTA BJS contact info |
ES (BARCELONA) | participant | 0.00 |
| 4 |
GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG GAB O
Organization address
address: Oskar-von-Miller-Ring 29 contact info |
DE (MUENCHEN) | participant | 0.00 |
| 5 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 0.00 |
| 6 |
INSTYTUT BIOLOGII DOSWIADCZALNEJ IM. M. NENCKIEGO POLSKIEJ AKADEMII NAUK
Organization address
address: UL. LUDWIKA PASTEURA 3 contact info |
PL (WARSZAWA) | participant | 0.00 |
| 7 |
LUNDS UNIVERSITET
Organization address
address: Paradisgatan 5c contact info |
SE (LUND) | participant | 0.00 |
| 8 |
NsGene A/S
Organization address
address: BALTORPVEJ 154 contact info |
DK (BALLERUP) | participant | 0.00 |
| 9 |
PAION DEUTSCHLAND GMBH
Organization address
address: MARTINSTRASSE 10-12 contact info |
DE (AACHEN) | participant | 0.00 |
| 10 |
QUICK COOL AB
Organization address
address: SCHEELEVAGEN BETA 6 IDEON SCIENCE PARK 17 contact info |
SE (LUND) | participant | 0.00 |
| 11 |
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Organization address
address: SEMINARSTRASSE 2 contact info |
DE (HEIDELBERG) | participant | 0.00 |
| 12 |
SYGNIS BIOSCIENCE GMBH & CO. KG
Organization address
address: Im Neuenheimer Feld 515 contact info |
DE (HEIDELBERG) | participant | 0.00 |
| 13 |
THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
UK (MANCHESTER) | participant | 0.00 |
| 14 |
UNIVERSITAET ZU LUEBECK
Organization address
address: RATZEBURGER ALLEE 160 contact info |
DE (LUEBECK) | participant | 0.00 |
| 15 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | participant | 0.00 |
| 16 |
UNIVERSITAETSKLINIKUM HEIDELBERG
Organization address
address: IM NEUENHEIMER FELD 672 contact info |
DE (HEIDELBERG) | participant | 0.00 |
| 17 |
UNIVERSITEIT GENT
Organization address
address: SINT PIETERSNIEUWSTRAAT 25 contact info |
BE (GENT) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Stroke poses a massive clinical, social and economic burden, yet we have very limited effective therapies. This inadequacy is in spite of intensive research efforts and numerous failed clinical trials. Leading European stroke researchers and clinicians with a track record of established cooperation will share their complementary expertise, and team up with SME partners with high profile R&D and ongoing, promising clinical trials. Based on a thorough reexamination of the failures and bottlenecks of previous attempts to develop effective therapies for stroke, the ARISE consortium proposes an integrative and innovative approach to overcome the translational roadblock. ARISE research will result in a number of novel, promising therapies, including safer thrombolytics, modulators of the immune system and inflammation, compounds inducing or mimicking endogenous neuroprotection, therapies to induce repair of lost function, as well as a fast way to selectively cool the brain. We will work on a common model and methods platform, in which for the first time relevant comorbidities, gender, age, and long term outcomes will be investigated. Training of young researchers will lead to a standardisation and harmonisation of laboratory practices within the consortium, and implement the standard operating procedures generated by the consortium. Importantly, the ARISE consortium combines expertise in clinical as well as preclinical stroke research. To obtain clinical proof of principle and to translate our findings into effective therapy of stroke, ARISE is conducting clinical trials and has established a dedicated clinical platform to (1) provide advice to the basic researchers of the consortium with regard to clinically relevant questions and modelling, (2) to periodically review the ongoing development of innovative therapies, and to (3) ultimately take the most promising preclinical strategy developed by the ARISE consortium into a multicenter randomized clinical trial.'
Introduzione (Teaser)
Nearly 15 million people worldwide suffer from an ischaemic episode (stroke), 5 million of whom die. Novel treatments are therefore needed to tackle these dismal statistics and improve the outcome of stroke sufferers.
Altri progetti dello stesso programma (FP7-HEALTH)
TISS.EU (2008)
"Evaluation of Legislation and Related Guidelines on the Procurement, Storage and Transfer of Human Tissues and Cells in the European Union – an Evidence-Based Impact Analysis"
Read MoreRANGER (2008)
"Rapid, robust & scaleable platform technology for fully automated reference laboratory grade Polymerase Chain Reaction (PCR) based diagnostics regardless of global setting"
Read MoreEPIDIACAN (2010)
Development of sensitive methodologies for exploitation of early epigenetic marker diagnosis in major types of cancer
Read More